SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

3 evidence topics · 2 sources

Neurodevelopmental and motor symptoms

“Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency.” (opens the source at this quote in a new tab)

Structural brain abnormalities

“ventriculomegaly, dysgenesis of the corpus callosum” (opens the source at this quote in a new tab)

Epilepsy

“Lifetime epilepsy was present in 16/41 (39%) of individuals.” (opens the source at this quote in a new tab)